Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Erik Ames
A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry
1 INTRODUCTION Natural killer (NK) cell neoplasms comprise a heterogeneous group of disorders ranging from indolent NK-large granular lymphocytic leukemia (NK-LGLL) to highly aggressive entities such as aggressive NK cell leukemia (ANKL) and extranodal NK/T-cell lymphoma (ENKTL) (El Hussein et al., 2020; Marchand et al., 2024; Semenzato et al., 2025; World Health Organization [WHO] Classification of Tumours Editorial Board, 2024).
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
|
Abstract There is limited systemic data on the dynamics of BCMA-target antigen expression with BCMA CAR-T at relapse. We analyzed 76 patients receiving standard-of-care BCMA-directed CAR-T who underwent real-time BCMA expression evaluation at baseline (n = 50), relapse (6), or both (20) using flow cytometry (FC) and/or immunohistochemistry (IHC). BCMA was universally expressed at baseline with significant heterogeneity in expression level.
By Masooma Rana, Sebastian Fernandez-Pol, Alexandria M. Jensen, Arash Velayati, Jean S. Oak, Oscar Silva, Erik Ames, Lori Muffly, Bita Sahaf, Sally Arai, Vanessa Kennedy, Sushma Bharadwaj, David J. Iberri, Michaela Liedtke, Yasodha Natkunam, Parveen Shiraz, Wen-Kai Weng, Melody Smith, Matthew Frank, Crystal L. Mackall, Saurabh Dahiya, Lekha Mikkilineni, David Miklos, Hitomi Hosoya, Surbhi Sidana, Vanna Hovanky
|
Nature
Verified
[2602.04046] Fast, Unsupervised Framework for Registration Quality Assessment of Multi-stain Histological Whole Slide Pairs
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Analysis of the impact of handling and culture on the expansion and functionality of NK cells
1 Introduction The infusion of T cells engineered to express chimeric antigen receptors (CARs) was first authorized by the United States Food and Drug Administration (FDA) to treat B-cell acute lymphoblastic leukemia (ALL) in the year 2017 (1, 2). Although CAR-T technology has demonstrated success in treating several cancer types (3), it presents certain limitations such as occasionally causing cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) (4).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Erik
Contact Erik, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack